Navigation Links
Microfluidics Announces Two New Board Members
Date:3/8/2010

NEWTON, Mass., March 8 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU), the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation, announced today the appointment of Henry Kay and Stephen J. Robinson to its Board of Directors.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO )

Mr. Kay has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs and Strategic Planning at companies such as Schering-Plough, Allergan Europe and American Home Products. He retired from Boston Scientific in 2006, where he served as Group VP of New Market Development / Strategic Planning, Endosurgery, and is currently the U.S. Partner of Medica Venture Partners, a healthcare dedicated VC based in Israel. Mr. Kay is a fellow of the Royal Society of Medicine (UK) and serves on the Boards of several startup healthcare companies. He holds a Bachelors Degree in Chemistry from Augusta College, a Masters of Science Degree from Rutgers University and an MBA in International Marketing from Seton Hall University. His significant international and pharmaceutical experience will help guide the global efforts of Microfluidics.

Mr. Robinson is currently Vice President, SAFC Hitech at Sigma Aldrich. In 2007, Sigma Aldrich purchased Epichem, Inc., a high-tech supplier of chemical processors to the semiconductor market, where Mr. Robinson served as CEO. There, he grew sales from $37M to $72M (including 60% growth in Asia) and turned the company from negative profitability to 15% EBITDA over three years. Like Mr. Kay, he has a distinguished history of successful international experience, having worked in multiple European and Asian locations. Mr. Robinson has extensive experience in managing business strategies for the chemical and material science industries, and has a proven record of leading M&A activities, including several deals for Rohm and Haas which resulted in a $2 billion electronic materials platform. Mr. Robinson received his Bachelors of Science in Chemical Engineering from the University of Leeds in the UK.

Mr. Kay and Mr. Robinson will join the Board consisting of Michael C. Ferrara, Leo Pierre Roy, Eric G. Walters and Chairman George Uveges.

"I am pleased to welcome Mr. Kay and Mr. Robinson to our Board of Directors," said Mr. Uveges. "Each brings substantial collective international experience and demonstrated strategic leadership in business segments that are growth opportunities for Microfluidics which will be an asset to the team as we continue to work toward achieving sustained profitability and growth."

"Our Board and our Company got stronger today," said Michael C. Ferrara, President and CEO of Microfluidics. "In 2009, we improved product quality and volume, streamlining costs, raising margins and enhancing sales and marketing efforts. As we turn to 2010 and beyond, we are focused on sustained growth. Mr. Kay and Mr. Robinson will help us achieve our goals by leveraging their experience and proven track records of success. I'm excited to begin working with them on the future of our Company."

ABOUT MICROFLUIDICS INTERNATIONAL CORPORATION

Microfluidics International Corporation (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.

By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit www.microfluidicscorp.com.

SOURCE Microfluidics International Corporation

Back to top

RELATED LINKS
http://www.microfluidicscorp.com

'/>"/>

SOURCE Microfluidics International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
2. Microfluidics International Corporation to Report Fourth Quarter and Year-end 2009 Financial Results on February 23, 2010
3. Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada
4. Lexicon Announces Proposed $95 Million Common Stock Offering
5. ThermalTherapeutic Systems Announces FDA Clearance of the VERATHERM(TM) Portable Hyperthermic Perfusion System
6. Millstone Medical Outsourcing Announces Addition of New Director of Manufacturing Engineering
7. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
8. Neurocrine Announces Proposed Public Offering of Common Stock
9. UBM Announces Plans for Japan Pharma & Bio Events
10. Renhuang Announces Fiscal Year 2010 Guidance
11. Shengtai Pharmaceutical, Inc Announces Appointment of New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
Breaking Medicine News(10 mins):